|
|
||||||||
| ||||||||||||||||||
This item has the following additional materials available:
Supplementary Data Figure 1 - PDF File
Human neutrophil chemotaxis to fMLP and LTB4 is potently inhibited by ATLa.
Chemotaxis of human neutrophils to 10 nM fMLP (left panel) or 10 nM LTB4 (right panel) was performed as described in Materials and Methods. The % inhibition of chemotaxis by ATLa (solid circles) and an LTB4 receptor antagonist (open circles) was determined with increasing compound concentration. Neutrophils were incubated with compounds for 30 minutes prior to chemotaxis assay. Each point represents the mean ± SEM of 3 separate experiments performed in triplicate.
Supplementary Data Figure 2 - PDF File
ATLa inhibits calcium ionophore-induced ear inflammation in mice and guinea pigs.
(A) Calcium ionophore-induced inflammation in mouse ears and measurement of edema, granulocyte and neutrophil infiltration was measured at 24 hrs as described in Materials and Methods. Inhibition of inflammation by ATLa (black bars) was compared to LTB4R-Ant (gray bars) and to the effects of methylprednisolone aceponate (MPA) (open bars). All compounds were co-applied with calcium-ionophore. Results are expressed as mean ± SEM of n = 10. * P < 0.05. (B) Ears of guinea pigs were treated as in (A) with ATLa (filled bars) or LTB4R-Ant (open bars) and assessed for edema formation and cell infiltration. Results are expressed as mean ± SEM of n = 10. * P < 0.05 versus vehicle control.
Supplementary Data Figure 3 - PDF File
ATLa suppresses ear inflammation induced by croton oil.
Croton-oil inflammation in mouse ears and measurement of edema, granulocyte and neutrophil infiltration was measured at 24 hrs as described in Materials and Methods. Inhibition of inflammation by ATLa (black bars) was compared to the LTB4 antagonist LTB4R-Ant (gray bars) and to the effects of methylprednisolone aceponate (MPA, open bars). All compounds were co-applied with croton oil. Results are expressed as mean ± SEM of n = 11. * P < 0.05.
Prepared by: the Data Supplement Manager
| ||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |